Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer

K. Shitara, T. Fleitas, H. Kawakami, G. Curigliano, Y. Narita, F. Wang, S. O. Wardhani, M. Basade, S. Y. Rha, W. I. Wan Zamaniah, D. L. Sacdalan, M. Ng, K. H. Yeh, P. Sunpaweravong, E. Sirachainan, M. H. Chen, W. P. Yong, J. L. Peneyra, M. N. Ibtisam, K. W. LeeV. Krishna, R. R. Pribadi, J. Li, A. Lui, T. Yoshino, E. Baba, I. Nakayama, G. Pentheroudakis, H. Shoji, A. Cervantes, C. Ishioka, E. Smyth

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer (GC), published in late 2022 and the updated ESMO Gastric Cancer Living Guideline published in July 2023, were adapted in August 2023, according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with GC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with GC representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), coordinated by ESMO and the Japanese Society of Medical Oncology (JSMO). The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different Asian regions represented by the 10 oncological societies. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with GC across the different regions of Asia, drawing on the evidence provided by both Western and Asian trials, whilst respecting the differences in screening practices, molecular profiling and age and stage at presentation. Attention is drawn to the disparity in the drug approvals and reimbursement strategies, between the different regions of Asia.

Original languageEnglish
Article number102226
JournalESMO Open
Volume9
Issue number2
DOIs
Publication statusPublished - Feb 2024

Keywords

  • ESMO
  • gastric cancer
  • guidelines
  • Pan-Asian
  • treatment

Fingerprint

Dive into the research topics of 'Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer'. Together they form a unique fingerprint.

Cite this